Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

Bibliography

• American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care 26(Suppl. 1), S83–S86, (2003)
   Google Scholar
• Tomkin GH. Targets for intervention in dyslipidemia in diabetes. Diabetes Care 31 (Suppl. 2), S241–S248 (2008)
   Google Scholar
• Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM 99, 1–14 (2011)
   Google Scholar
• National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002)
   Google Scholar
• Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid. Res. 43, 1363–1379 (2002)
   Google Scholar
• Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123, 43–56 (1996)
   Google Scholar
• Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid. Res. 39, 1263–1273 (1998)
   Google Scholar
• Camejo G, Lopez A, Lopez F, Quinones J. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 55, 93–105 (1985)
   Google Scholar
• Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am. J. Med. 110, 103–110 (2001)
   Google Scholar
• Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93, 189–199 (1992)
   Google Scholar
• de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11, 298–306 (1991)
   Google Scholar
• Owens D, Maher V, Collins P, Johnson A, Tomkin GH. Cellular cholesterol regulation: a defect in the Type-2 (non-insulin dependent) diabetic patient in poor metabolic control. Diabetologia 33, 93–99 (1990)
   Google Scholar
• Dimitriadis E, Griffin M, Owens D, Johnson A, Collins P, Tomkin GH. Oxidation of low density lipoprotein in non-insulin dependent diabetes: its relationship to fatty acid composition. Diabetologia 38, 1300–1306 (1995)
   Google Scholar
• Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient. Atherosclerosis 102, 63–67 (1993)
   Google Scholar
• Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an atherogenic modification of LDL. Curr. Opin. Lipidol. 19, 378–384 (2008)
   Google Scholar
• St Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the longterm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec cardiovascular study. Arterioscler. Thromb. Vasc. Biol. 25, 553–559 (2005)
   Google Scholar
• Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89–94 (2002)
   Google Scholar
• Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the stanford coronary risk intervention project. Circulation 94, 2146–2153 (1996)
   Google Scholar
• Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipasemediated changes in LDL density. Circulation 99, 1959–1964 (1999)
   Google Scholar
• Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 85, 37–45 (1992)
   Google Scholar
• Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and the treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 92, 1779–1785 (1995)
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: veterans affairs high-density lipoprotein cholesterol intervention trials study group. N. Engl. J. Med. 341, 410–418 (1999)
   Google Scholar
• Keech A, Simes RJ, Barter P et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type-2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005)
   Google Scholar
• Shafrir E, Raz I. Diabetes: mellitus or lipidus? Diabetologia 46, 433–440 (2003)
   Google Scholar
• Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988)
   Google Scholar
• Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl. 1), SI20–SI23, (1997)
   Google Scholar
• U.K. Prospective Diabetes Study 27. Plasma Lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20, 1683–1687 (1997)
   Google Scholar
• Friedlander Y, Kidron M, Caslake M, Lamb T, McConnell M, Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 148, 141–149 (2000)
   Google Scholar
• Austin MA, Mykkanen L, Kuusisto J et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92, 1770–1778 (1995)
   Google Scholar
• Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 92, 141–146 (1993)
   Google Scholar
• Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12, 1496–1502 (1992)
   Google Scholar
• Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in Type-2 diabetes. Metabolism 54, 227–234 (2005). n Demonstrates that small, dense LDL is an independent marker of clinically apparent and nonapparent atherosclerosis in patients with Type 2 diabetes
   Google Scholar
• Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am. J. Epidemiol. 146, 483–494 (1997)
   Google Scholar
• Craven TE, Ryu JE, Espeland MA et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case–control study. Circulation 82, 1230–1242 (1990)
   Google Scholar
• Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87, II56–II65 (1993)
   Google Scholar
• Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR 3rd. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler. Thromb. 11, 1786–1794 (1991)
   Google Scholar
• Goya K, Kitamura T, Inaba M et al. Risk factors for asymptomatic atherosclerosis in Japanese Type-2 diabetic patients without diabetic microvascular complications. Metabolism 52, 1302–1306 (2003)
   Google Scholar
• Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M. Carotid artery intima–media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27, 1986–1992, (1996)
   Google Scholar
• Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with Type-2 diabetes. Exp. Clin. Endocrinol. Diabetes 115, 477–482 (2007)
   Google Scholar
• Winkler K, Abletshauser C, Hoffmann MM et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with Type-2 diabetes mellitus: baseline LDL profile determines specific mode of action. J. Clin. Endocrinol. Metab. 87(12), 5485–5490 (2002)
   Google Scholar
• Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in Type-2 diabetes. Diabetes Res. Clin. Pract. 59(3), 181–189 (2003)
   Google Scholar
• Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp. Clin. Endocrinol. Diabetes 110(4), 182–187 (2002)
   Google Scholar
• Freed MI, Ratner R, Marcovina SM et al. Rosiglitazone study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type-2 diabetes mellitus. Am. J. Cardiol. 90(9), 947–952 (2002)
   Google Scholar
• Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/Type-2 diabetes. Metabolism 51(3), 334–342 (2002)
   Google Scholar
• Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 88(7), 3212–3217 (2003)
   Google Scholar
• Ikejiri A, Hirano T, Murayama S et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 53(9), 1113–1117 (2004)
   Google Scholar
• Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in Type-2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol.87(1), 44–48 (2001)
   Google Scholar
• Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 50(8), 983–988 (2001)
   Google Scholar
• Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al. CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in Type-2 diabetic patients with ischaemic heart disease. Atherosclerosis 167, 243–255 (2003)
   Google Scholar
• Lahdenpera S, Tilly-Kiesi M, Vuorinen- Markkola H, Kuusi T, Taskinen MR. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution and composition in patients with type II diabetes. Diabetes Care 16, 584–592 (1993)
   Google Scholar
• O(Neal DN, O(Brien RC, Timmins KL et al. Gemfibrozil treatment increases low-density lipoprotein particle size in Type-2 diabetes mellitus but does not alter in vitro oxidizability. Diabet. Med. 15, 870–877 (1998)
   Google Scholar
• Kondo A, Morita H, Nakamura H et al. Influence of fibrate treatment on malondialdehyde-modified LDL concentration. Clin. Chim. Acta 339, 97–103 (2004)
   Google Scholar
• Hayashi K, Kurushima H, Kuga Y et al. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance. Cardiovasc. Drugs Ther. 12, 3–12 (1998)
   Google Scholar
• Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogenic lipoprotein phenotype in Type-2 diabetes: reversal with micronised fenofibrate. Diabetes Metab. Res. Rev. 15, 395–399 (1999)
   Google Scholar
• Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution and hemorheologic parameters in Type-2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87, 44–48 (2001)
   Google Scholar
• Tan CE, Chew LS, Tai ES et al. Benefits of micronised fenofibrate in Type-2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 154, 469–474 (2001)
   Google Scholar
• Vakkilainen J, Steiner G, Ansquer JC et al. DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107, 1733–1737 (2003)
   Google Scholar
• Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes. Metab. 4, 255–261 (2002)
   Google Scholar
• Pan J, Van JT, Chan E, Kesala RL, Lin M, Charles MA. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism 51, 1120–1127 (2002)
   Google Scholar
• Patti L, Maffettone A, Iovine C et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 146, 361–367 (1999)
   Google Scholar
• Petersen M, Pedersen H, Major-Pedersen A, Jensen T, Marckmann P. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in Type-2 diabetic patients. Diabetes Care 25, 1704–1708 (2002)
   Google Scholar
• Mostad IL, Bjerve KS, Lydersen S, Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with Type II diabetes. Eur. J. Clin. Nutr. 62(3), 419–429(2007)
   Google Scholar
• Woodman RJ, Mori TA, Burke V et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive Type-2 diabetic patients. Diabetes Care 26, 253 (2003)
   Google Scholar
• Farnier M, Freeman MW, Macdonell G et al. The Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26, 897–905 (2005)
   Google Scholar
• Hayashi T, Hirano T, Yamamoto T, Ito Y, Adachi M. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with Type-2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism 55, 879–884 (2011)
   Google Scholar
• Chu NV, Kong AP, Kim DD et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type-2 diabetes. Diabetes Care 25, 542–549 (2002)
   Google Scholar
• Inoue I, Shinoda Y, Nakano T et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 55, 946–952 (2011)
   Google Scholar
• Winkler K, Friedrich I, Baumstark MW, Wieland H, Marz W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with Type-2 diabetes mellitus. Br. J. Diabetes Vasc. Dis. 2, 1431–1448 (2002)
   Google Scholar
• Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with Type-2 diabetes. Diab. Vasc. Dis. Res. 1, 44–50 (2004)
   Google Scholar
• Parhofer KG, Otto C, Geiss HC et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus Type-2 – results of a pilot study. Exp. Clin. Endocrinol. Diabetes 113, 49–52 (2005)
   Google Scholar
• Lautamaki R, Nuutila P, Airaksinen KE et al. The Effect of PPARg-Agonism on LDL subclass profile in patients with Type-2 diabetes and coronary artery disease. Rev. Diabet. Stud. 3, 31–38 (2011)
   Google Scholar
• Yu D, Murdoch SJ, Parikh SJ et al. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with Type-2 diabetes on statin therapy. Diab. Vasc. Dis. Res. 3, 189–196 (2011)
   Google Scholar
• Albaladejo Otŏn MD, Calle Luna JG, Granero Fernández E, Hernández Martìnez AM, Parra Pallarès S, Martìnez Hernández P. [LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus Type-2.] Med. Clin. (Barc.) 132, 98–101 (2011)
   Google Scholar
• Rizzo M, Vekic J, Koulouris S et al. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in Type-2 diabetes. Angiology 61, 584–590 (2010)
   Google Scholar
• Rizzo M, Christ ER, Rini GB, Spinas GA, Berneis K. The differential effects of thiazolidindiones on atherogenic dyslipidemia in Type-2 diabetes: what is the clinical significance ? Expert Opin. Pharmacother. 9, 2295–2303 (2008)
   Google Scholar
• Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with Type-2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab. Res. Rev. 23, 392–399 (2007)
   Google Scholar
• Deeg MA, Buse JB, Goldberg RB et al. On behalf of the GLAI study investigators. pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type-2 diabetes and dyslipidemia. Diabetes Care 30, 2458–2464 (2007). n Demonstrates that pioglitazone has strong effects on diabetic dyslipidemia in a large randomized trial
   Google Scholar
• Berneis K, Rizzo M, Stettler C et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type-2 diabetes. Expert Opin. Pharmacother. 9, 343–349 (2008)
   Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and antiatherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4- inhibitors. Expert Opin. Inv. Drug 18, 1495–1503 (2011). n Summarizes the beneficial effects of incretin-based therapies on cardiovascular risk factors including plasma lipids, highlighting the need for future studies on the effects of such therapies on atherogenic lipoproteins, such as small, dense LDL
   Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type-2 Diabetes. N. Engl. J. Med. 358, 2545–2559 (2008)
   Google Scholar
• Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin. Lab. 55, 421–429 (2011)
   Google Scholar
• Mikhailidis DP, Elisaf MS, Rizzo M et al. ‘European Panel on Low Density Lipoprotein (LDL) Subclasses(: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533–571 (2011). nn A recent comprehensive and up to-date consensus statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses
   Google Scholar
• Mikhailidis DP, Elisaf MS, Rizzo M et al. (European Panel on Low Density Lipoprotein (LDL) Subclasses(: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol. 9(5), 531–532 (2011)
   Google Scholar
• Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr. Med. Res. Opin. 23, 1103–1111 (2007)
   Google Scholar
• Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv. Ther. 24, 575–582 (2007)
   Google Scholar
• Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc. Drugs Ther. 20, 205–217 (2011)
   Google Scholar
• Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ? Int. J. Clin. Pract. 63, 478–485 (2011)
   Google Scholar
• Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone vs. simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr. Med. Res. Opin. 27, 685–692 (2011)
   Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr. Med. Res. Opin. 27, 693–695 (2011)
   Google Scholar
• Rizzo M, Rini GB. Ezetimibe, cardiovascular risk and atherogenic dyslipidemia. Arch. Med. Sci. 7, 5–7 (2011)
   Google Scholar
• Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 31, 1633–1639 (2010)
   Google Scholar
• Schwartz SL, Ratner RE, Kim DD et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with Type-2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin. Ther. 30, 858–867 (2008)
   Google Scholar
• DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 24, 2943–2952 (2008)
   Google Scholar
• Matikainen N, Manttari S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type-2 diabetes. Diabetologia 49, 2049–2057 (2011)
   Google Scholar
• Schwartz EA, Koska J, Mullin MP et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset Type-2 diabetes mellitus. Atherosclerosis 212, 217–222 (2010)
   Google Scholar
• Bandsma RHJ, Lewis GF. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia. Atherosclerosis 212, 40–41 (2010)
   Google Scholar
• Parlevliet ET, Schroder-van der Elst JP, Corssmit EP et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat fed mice. J. Pharmacol. Exp. Ther. 328, 240–248 (2011)
   Google Scholar
• Nakano T, Inoue I, Seo M et al. Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat. Cardiovasc. Drug Discov. 4, 31–36 (2011)
   Google Scholar
• Inoue I, Awata T, Katayama S. Retrospective, observation study: quantitative and qualitative effect of ezetimibe and HMGCoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL? Recent Pat. Cardiovasc. Drug Discov. 5, 143–152 (2010)
   Google Scholar
• Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83, 59–67 (1990).
   Google Scholar